Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00446940 · ClinicalTrials.gov registry record · Phase 2
Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C
A Phase 2 study of Hepatitis C, sponsored by Bader, Ted, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00446940 is a Phase 2 study of Hepatitis C that has completed, run by Bader, Ted, M.D.. The registered enrollment target is 16 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00446940, a Phase 2 study of Hepatitis C, has completed, sponsored by Bader, Ted, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
Different Doses of rosuvastatin and atorvastatin will be used to see if HCV viral load changes and liver tests change.
Conditions Studied
Interventions
- DRUG rosuvastatin
- DRUG atorvastatin
Study Locations (1)
Oklahoma
- VA Hospital - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00446940
The ClinicalTrials.gov registry entry for NCT00446940 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower). The listed sponsor is Bader, Ted, M.D., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which rosuvastatin is the first listed.
NCT00446940 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.
Frequently Asked Questions
What is clinical trial NCT00446940 about?
NCT00446940 is a clinical study titled "Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C". Different Doses of rosuvastatin and atorvastatin will be used to see if HCV viral load changes and liver tests change.
What is the current status of trial NCT00446940?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2006-12. Estimated completion is 2007-03.
What conditions does trial NCT00446940 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT00446940?
The interventions under investigation include: rosuvastatin (DRUG), atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00446940?
This trial is sponsored by Bader, Ted, M.D., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00446940 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Expanding the Pool in Orthotopic Heart Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
COMPLETED · Phase 2
-
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
COMPLETED · Phase 2
-
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
COMPLETED · Phase 2
-
A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.